Earlier this month, I sat down for a Pulse Check with Dr. Patrick O’Shaughnessy, president and CEO of Catholic Health: a six ...
Knownwell picked up $25 million in fresh funding, riding the wave of investment in obesity care. | LAS VEGAS—Over the last 18 ...
Cipla collaboration brings a second brand of tirzepatide, Yurpeak, to India, aiming to widen patient access for diabetes and ...
Get the latest healthcare stock updates, key pharma deals, and major legal developments impacting the S&P 500.
Cipla and Lilly partner to distribute Yurpeak (tirzepatide) in India for type 2 diabetes and weight management. Broader ...
Under the agreement, Cipla will market the drug under a new brand name, Yurpeak, while Lilly continues to sell it as Mounjaro ...
India has about 101 million people living with diabetes and nearly half of these in the adult patients category are being ...
Lilly and Cipla announce a distribution agreement for Yurpeak, a drug for type 2 diabetes and weight management, enhancing ...
Two Texas compounding pharmacies are the latest to get sued in Eli Lilly’s multistate battle to stop sales of replica ...
In a move aimed at expanding access to obesity and diabetes care in India, Eli Lilly and Company (India) Pvt. Ltd. (Lilly) ...
PE: What makes TrumpRx different from other government-run health programs? O’Dell: TrumpRx is different in that its ...
New long-term extension data show approximately 80% of patients achieved or maintained meaningful skin improvement (EASI 75) with EBGLYSS with half the doses compared ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback